



### **Current State Assessment:** How/where/why to collect information?

Lisa Dell Aquila **Everett Center** 

Marisa D'Angeli

Pat Preston WA Dept of Health Center for Geriatric IC

Kristine Wallin WA State Soldiers Home

**Grant Walker** Mercury Pharmacy

February 22, 2017







### Housekeeping

#### Please...

- Mute your phone if you are not speaking
- Do not put the phone line on hold
- Use the chat box to ask questions during the presentation
- Use the open line at the end of the presentation for Q & A
- Use the webinar evaluation to offer feedback on today's presentation and make suggestions for future calls





#### **Outline**

- Nursing home gap survey
- Current state assessment
  - Case studies and discussion
- Q & A
- New EQuIP resources





### **EQuIP** is a Partnership













- Local Public Health Departments
- Washington Department of Social and Health Services
- Leading Age
- Washington Health Care Association
- NADONA
- And many others




### **SNF Gap Survey**



#### 7 Core Elements of AMS for NH

- Leadership commitment
- Accountability
- Drug expertise
- Action
- Tracking
- Reporting
- Education








## SNF Gap Survey on IP and AMS Resources


- Distributed to 212 Washington and 77 Idaho SNFs
- Open 12/13/16-1/30/17
- Total responses 94 (33% response rate)





### SNF Gap Survey— Leadership Commitment


71 (76%) have leadership support for AMS





### SNF Gap Survey— Leadership Commitment


• 71 (76%) have leadership support for AMS





### SNF Gap Survey— Accountability


• 72 (77%) have designated ASP leader





# SNF Gap Survey— Drug Expertise

• 65 (69%) have access to pharmacy expertise






# SNF Gap Survey— Actions

- 45 (48%) have policies to improve prescribing
- 63 (67%) have practices to improve antibiotic use



# SNF Gap Survey— Tracking


- 59 (63%) monitor antibiotic use
- 64 (68%) monitor outcomes of antibiotic use






### SNF Gap Survey— Reporting

 58 (62%) routinely report AU and outcomes to providers and nursing staff



### SNF Gap Survey— Education


• 57 (61%) provide AMS education





### SNF Gap Survey— Education

• 57 (61%) provide AMS education





#### **Gap survey**





#### **Current State Assessment**



### **Jump Start Stewardship Workbook**

## JumpStart Stewardship

Implementing Antibiotic Stewardship in

**Nursing Homes** 





#### **Current State Assessment**

- Show information for two different SNFs
- Discuss how and where to collect data
- Comment from experts on findings



## **Facility characteristics**

Last Calendar Year or Last 12 months	Number	Number
Licensed Beds	100	97
Admissions	403	47
Resident days	30,409	33,590
Average daily census	83.31	'92_
Number of unique prescribers	4	2,-
Clinical pharmacists (hours per month)	Visits quarterly	4 80
	Average Daily Census	Average Daily Census
Residents with indwelling urinary catheters	Current-20	12
Residents with tracheostomy	Current-11	<b>O</b> .
Residents with tracheostomy on ventilator	Current-16	SQ.
Pressure Injury ( Stage II-IV, unstageable and DTI)	ADC for 2016 of # res	23
	with PI's = 7.25	
	ADC for 2016 of # of PI's	
	for 2016= 19.67	4 total 29



### Multi drug resistant organisms

Last Calendar Year or Last 12 months	Number	Number
Clostridium difficile		
Number of facility-onset C. difficile infections	11	2
Number of community-onset C. difficile infections	7	Ĭ
Methicillin-Resistant Staphylococcus aureus (MRSA)		
Number of non-duplicate MRSA isolates	CAI=7, HAI=1, Total=8	3
Vancomycin-Resistant Enterococcus (VRE)		
Number of non-duplicate VRE isolates	CAI=1, HAI=2, Total=3	8
Multidrug-Resistant Gram-Negative Bacteria		
Number of non-duplicate Klebsiella species isolates resistant to 3rd	ESBL Klebsiella	
generation cephalosporins* (Our CP-CRE was Klebsiella pnot	pneumoniae	i i
included in these numbers)	CAI=2, HAI=2, Total=4	
Number of non-duplicate Escherichia coli isolates resistant to 3rd	ESBL e. coli	
generation cephalosporins*	CAI=5, HAI=2, Total=7	
Number of non-duplicate Pseudomonas aeruginosa isolates	MDRO w/o ESBL:	
resistant to 3 <sup>rd</sup> generation <u>cephalosporins</u> *	CAI=1, HAI=4, Total=5	(A)
	ESBL pseudomonas a.:	
	CAI=1, HAI=0, Total=1	
	Total of all=6	
Number of non-duplicate Acinetobacter baumanii isolates resistant	MDRO w/o ESBL:	Ī <u>.</u>
to 3 <sup>rd</sup> generation cephalosporins*	CAI=0, HAI=1, Total=1	Ser.
	ESBL Acinetobacter b.:	N.
	CAI=1, HAI=0, Total=1	<u>e</u>
	Total of all=2	
	1013101311-2	

<sup>\*</sup>Third generation cephalosporins include ceftriaxone, cefotaxime, ceftazidime, cefpodoxime, and cefdini



Last Calendar Year or Last 12 months	Number	Number
Multidrug-Resistant Gram-Negative Bacteria (continued)		moning
Number of non-duplicate Proteus mirabilis isolates resistant to 3rd	ESBL proteus m.	2
generation cephalosporins*	CAI=1, HAI=0, Total=1	<i>L</i>
Number of non-duplicate isolates of carbapenem-resistant	CAI=0, HAI=1, Total=1	2
Enterobacteriaceae		
Number of non-duplicate Pseudomonas aeruginosa isolates	1 HAI MDRO	
resistant to carbapenems	pseudomonas a. isolated.	1
	Resistant to everything on	
	sensitivity panel, including	
	ceftazidime and	
	cefpodoxime. Not tested	
	against carbapenems.	
Number of non-duplicate Acinetobacter baumanii isolates resistant	1 patient admitted with	`~
to carbapenems	Dx of "MDRO	<b>Q</b>
	Acinetobacter b."	
	Sensitivity panel not	
	available.	
	1 HAI MDRO	
	Acinetobacter b. which	
	was resistant to 3 <sup>rd</sup>	
	generation cephalosporins	
	and sensitive only to	
	Imipenem and	
	Gentamicin.	
	Total of 2 MDRO	
	Acinetobacter b.	
Other MDROs of Concern		
MDRO Achromobacter xylosoxidans	CAI=0, HAI=1, Total=1	
MDRO Serratia marcescens	CAI=0, HAI=1, Total=1	Washington State Di

**Core elements of Stewardship** 

			core cicilicitis of stewart	<b>4311</b>	
LE	ADERSHIP SUPPORT	Γ			CHARLES OF STREET
1.	Can your facility demonstrate leadership support for antibiotic stewardship through one or more of the actions listed at right?	YES NO	If yes, indicate which actions (select all that apply)  Written statement of leadership support to improve antibiotic use  Antibiotic stewardship duties included in Medical Director position description  Antibiotic stewardship duties included in Director of Nursing position description  Leadership monitors whether antibiotic stewardship policies are followed  Antibiotic use and resistance data are reviewed in quality/performance improvement meetings	YES NO	If yes, indicate which actions (select all that apply)  Written statement of leadership support to improve antib Antibiotic stewardship duties included in Medical Director description  Antibiotic stewardship duties included in Director of Nursi description  Leadership monitors whether antibiotic stewardship policifollowed  Antibiotic use and resistance data are reviewed in quality/performance improvement meetings
AC	COUNTABILITY				
2.	Has your facility identified one or more leaders for antibiotic stewardship activities?	YES NO	If yes, indicate who is accountable for stewardship activities (select all that apply)  Medical Director Director or Assistant Director of Nursing Services Consultant pharmacist Infection Prevention and Control Officer / Infection Preventionist Quality Improvement Officer Staff Development Coordinator Other:	YES D NO	If yes, indicate who is accountable for stewardship activities (select all that apply)  Medical Director Director or Assistant Director of Nursing Services Consultant pharmacist Infection Prevention and Control Officer / Infection Prevention
DF	RUG EXPERTISE				
3.	Does your facility have access to individual(s) with antibiotic stewardship expertise?	YES NO	If yes, indicate who is accountable for stewardship activities (select all that apply)  Consultant pharmacist Stewardship team at local hospital Infectious disease/stewardship consultant Medical Director Corporate support/nurse consultant Other:	YES D NO	If yes, indicate who is accountable for stewardship activities (select all that apply)  Consultant pharmacist Stewardship team at local hospital Infectious disease/stewardship consultant Medical Director Corporate support/nurse consultant Other:
					<sup>24</sup> Health

#### ACTIONS TO IMPROVE ANTIBIOTIC USE

		If yes, indicate which policies are in place (select all that apply)		If yes, indicate which policies are in place (select all that a
policies to improve antibiotic	YES NO	Requirement for prescribers to document a dose, duration, and indication for all antibiotic prescriptions  Facility approved-algorithm for assessing residents  Facility-approved algorithms for appropriate diagnostic testing (e.g., obtaining cultures) for specific infections  Facility-specific treatment recommendations or order sets for one or more infectious syndrome  Antibiotic use limited to agents listed on the medication formulary  Pre-approval required for certain antibiotics  Other:	YES NO	Requirement for prescribers to document a dose, do indication for all antibiotic prescriptions Facility approved-algorithm for assessing residents Facility-approved algorithms for appropriate diagnotobtaining cultures) for specific infections Facility-specific treatment recommendations or order more infectious syndrome Antibiotic use limited to agents listed on the medicator Pre-approval required for certain antibiotics Other:
implemented practices to improve	YES NO	Facility-approved algorithms or decision support tools are routinely used to assess residents suspected of having an infection (e.g., AHRQ UTI SBAR tool)-Have CAUTI and UTI algorithms, URI algorithm in development  Delirium assessment tool is routinely used for residents to aid in differentiating infectious from non-infectious causes of delirium  Staff routinely communicate antibiotic use, infection and colonization status when residents are transferred to/from other healthcare facilities-Frequency only yearly, and not facility-specific  Staff routinely use a local or facility-specific antibiogram to guide selection of an antibiotic treatment-in progress  Staff routinely review antibiotic orders in conjunction with culture results and an updated assessment of clinical symptoms within 72 hours of starting antibiotics ("antibiotic timeout") in order to determine whether de-escalation or stopping therapy is indicated  Staff routinely document clinical assessment with all antibiotic starts  Staff routinely document whether residents with suspected UTI have signs and symptoms that meet the updated McGeer surveillance definition for UTI  Staff routinely use antibiotic order sets for common infectious syndromes to improve antibiotic use Indicate for which condition(s):  Other:  Other:	YES NO	If yes, indicate which practices are in place (select all that  Facility-approved algorithms or decision support too used to assess residents suspected of having an infection used to assess residents suspected of having an infection of the UTI SBAR tool)  Delirium assessment tool is routinely used for reside differentiating infectious from non-infectious causes  Staff routinely communicate antibiotic use, infection status when residents are transferred to/from other facilities  Staff routinely use a local or facility-specific antibiogus selection of an antibiotic treatment  Staff routinely review antibiotic orders in conjunction results and an updated assessment of clinical symptom hours of starting antibiotics ("antibiotic timeout") in determine whether de-escalation or stopping theraped Staff routinely document clinical assessment with all Staff routinely document whether residents with sussigns and symptoms that meet the updated McGeer definition for UTI  Staff routinely use antibiotic order sets for common syndromes to improve antibiotic use Indicate for which condition(s):  Other:  Other:

#### ACTIONS TO IMPROVE ANTIBIOTIC USE (continued)

	If yes, indicate activities performed by the consultant pharmacist (select all that apply)		If yes, indicate activities performed be (select all that apply)
6. Does your consultant pharmacist support antibiotic stewardship activities? YES	Reviews antibiotic courses for appropriateness of administration and/or indication  Establishes standards for clinical/laboratory monitoring for adverse drug events from antibiotic use  Reviews microbiology culture data to assess and guide antibiotic selection	⊠ YES	Reviews antibiotic courses for a and/or indication  Establishes standards for clinica drug events from antibiotic use  Reviews microbiology culture d selection
pharmacy manager and consultant pharmacist on this.	If yes, how often do pharmacy consults occur?  Monthly Weekly On antibiotic order Other: Quarterly	NO	If yes, how often do pharmacy cons  Monthly  Weekly  On antibiotic order  Other:



TI	RACKING: MONITOR	ING A	NTIBIOTIC PRESCRIBING, USE, AND RESISTANCE	NG AI	NTIBIOTIC PRESCRIBING, USE
7.	Does your facility monitor one or more measures of antibiotic use?	YES NO	If yes, indicate which of the following are being tracked (select all that apply)  Adherence to clinical assessment documentation (signs/symptoms, vital signs, physical exam findings)  Adherence to prescribing documentation (dose, duration, indication)  Adherence to facility-specific treatment recommendations  Regular point-prevalence surveys of antibiotic use  Number new antibiotic starts per 1,000 resident-days  Number antibiotic days of therapy per 1,000 resident-days (all antibiotic or by select antibiotic class)  Other:	YES INO	If yes, indicate which of the following a (select all that apply)  Adherence to clinical assessment vital signs, physical exam findings  Adherence to prescribing document of the company
8.	Does your facility monitor one or more outcomes of antibiotic use?	YES NO	If yes, indicate which of the following are being tracked (select all that apply)  Monitors rates of C. difficile infection  Monitors rates of antibiotic-resistant organisms  Monitors rates of adverse drug events due to antibiotics  Other:	YES NO	If yes, indicate which of the following (select all that apply)  Monitors rates of <i>C. difficile</i> infection of the following



REPORTING TO STAFF	ON IN	MPROVING ANTIBIOTIC USE AND RESISTANCE		
9. Does your facility provide facility-specific reports on antibiotic use and outcomes to clinical providers and nursing staff?	YES NO	If yes, indicate which of the following are being tracked (select all that apply)  Measures of antibiotic use at the facility  Measures of outcomes related to antibiotic use (i.e., <i>C. difficile</i> rates)  Report of facility antibiotic susceptibility patterns (within last 18 months)  Personalized feedback on antibiotic prescribing practices (to clinical providers)  Monitor documentation of clinical assessments  Other:	₽ YES NO	If yes, indicate which of the following are being (select all that apply)  Measures of antibiotic use at the facility (select all that apply)  Measures of outcomes related to antibing (select all that apply)  Report of facility antibiotic susceptibility months)  Personalized feedback on antibiotic preproviders)  Monitor documentation of clinical assess  Other:
EDUCATION				
10. Does your facility provide educational resources and materials about antibiotic resistance and opportunity for improving antibiotic use?	YES NO	☐ If yes, indicate which groups receive these resources (select all that apply). Clinical providers (e.g., MDs, NPs, PAs, PharmDs) ☐ Nursing staff (e.g., RNs, LPNs, CNAs) ☐ Residents and families ☐ Other:	YES NO	If yes, indicate which groups receive the apply). Clinical providers (e.g., MDs, NP)  Nursing staff (e.g., RNs, LPNs, CNAs)  Residents and families  Other:  If yes, how often does your facility provide estewardship? (select all that apply)  At hire  Annually  Quarterly  Monthly  As Needed

This questionnaire was adapted from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs in Nursing ed from the CDC's Core Elements of Antibiotic Stewardship Programs i



## Most common infectious clinical syndromes (past 12 months)

Туре	#	Abx 1	Abx 2	Abx 3	
UTI	26	Nitro- furan	Amox- clav	Bactrim	
Resp (incl PNA, VAP, ILI)	36	Pip- taz	Cefe- pime	Vanco	
SSTI	14	Cefa- lexin	Bactrim cefazolin minocycline meropenem levoflox		
GI	12	Flagyl	Vanco- mycin		

Type	#	Abx 1	Abx 2	Abx 3
UTI	30+	Cipro	Sulfa- methox	Amox- clav
URI	25+	Ceftriax	Levo- flox	Doxy- cycline
PNA	10+	Ceftriax	Levo- flox	Amox- clav
Cellulitis	30+	Sulfa- methox	Amox	Cipro- flox



#### Most often prescribed antibiotics

IV Antibiotic	Utilization Last Calendar Year (grams)	Cost of Utilization Last Calendar Year	Notes	IV Antibiotic	Utilization Last Calendar Year (grams)
Zosyn	Given more time, I may be a pharmacy. Could not obta	able to obtain this info from in reasonably at this time.	Average cost of \$13.95/day	Rocephin	unknown
Cefepime	, ,	·	Average cost of \$7.70/day	V3WOMYCW	UNKNOWN
Vancomycin			Average cost of \$5.20/day		

PO Antibiotic	Utilization Last Calendar Year (grams)	Cost of Utilization Last Calendar Year	Notes	PO Antibiotic	Utilization Last Calendar Year (grams)
Macrobid		able to obtain this info from in reasonably at this time.	Average cost of \$1.00/day	Sulfamethoxazalo	unkneen
Bactrim			Average cost of \$0.15/day	Levo flox acin	unknum
Augmentin			Unknown cost/day	Ciorofloxacin	unknum
Keflex			Unknown cost/day	ADVOX TR-K QV	unknew
Flagyl			Unknown cost/day	Cohalexin	unknum
PO <u>Vanco</u>			Unknown cost/day	0. 11: 11:0	
				= Amoxicillin	



#### Barriers to improving antibiotic use

- Insufficient tracking software
- Incomplete symptom documentation or non-specific indication (ex. "infection")
- Excessive use of cultures
- Insistent family members
- Antibiogram not timely or facility-specific
- Lack of input from consultant pharmacist
- Provider fear of litigation
- Lack of provider confidence in staff ability to identify early signs of sepsis
- Idiopathic leukocytosis among ventilated patients
- No current specific surveillance criteria for VAP in LTCF
- Bed-lock (how to meet needs of community while following cohorting standards)



#### **New EQuIP Resources**

- Archived recording of webinars
- Jump Start Stewardship Workbook
- EQuIP enrollment form

Coming soon.....



#### **Enrollment Form**

- Formal participation encouraged (not mandatory)
- Signed enrollment form by facility leadership
- Track facility self-assessment
- Opportunity to participate in small group collaborative projects
  - Provide contact info
  - Share data with small group
  - Establish ASP & be recognized on DOH Honor Roll for Stewardship





#### Washington State Participant Agreeme

Count to trung term use a professional seveneupoment program everopeen in primers in with washington and idaho state and local health departments, Quality Health, and local chapters of the Association for Professionals in Infection Control (APIC) to equip staff in nursing homes to improve quality and safety of residents through education, mentorship, collaborative learning, and data sharing The program is offered to participating facilities in Wathington and Idaho at no charge.

#### As a participant in the program, your facility will receive the following

- Web-based education and training on antimicrobial stewardship and infection prevention an control specifically tailored to the needs of long term care facilities
- Access to expert consultants on antimicrobial stewardship and infection prevention and contr
   Customizable tools, templates, sample policies and other resources to support antimicrobial.
- stewardship and infection prevention and control activities in your nursing home

  Opportunities for networking and collaboration among peers in Washington and Ids
- There are two ways to participate in FOuID for LTC.

#### 1) Staff from your facility can call in to webinars and get access to tools and resources

- 2) Your facility can formally enroll in the program and commit to certain requirements:
- Provide current contact information for infection prevention, quality management staff a stewardship leads.
- Attend live and recorded web-based training modul
- Participate in facilitated peer-to-peer, collaborative learning and improvement activities Share outcome data from quality improvement projects with other members of the sma
- Complete a facility self-assessment upon enrollment in the program
- Complete an annual facility self-assessment annually
  - Achieve criteria to be recognized on the DOH Honor Roll for Stewardship in Nursing Homes o Criteria include meeting CDC 7 core elements for stewardship in nursing homes.

ning below, you attest to understanding the expectations and committing to participation in the Long Term Care program.

cong remi care program.	
Skilled Nursing Home Name:	City:
Executive Signature:	Date:



#### **Before next EQuIP webinar on March 22**

- Register for webinar series
- Share the registration link with your colleagues
- Enrollment form and Jump Start Stewardship
   Workbook will be emailed to all registrants when
   posted on DOH website
- Please send suggestions or requested topics to marisa.dangeli@DOH.wa.gov





## Q & A



